Sthree Share Discussion Threads

[cheading] 08/5/2007 20:21

Hindsight causes me to panic, foresight priceless. Track record of David Dodd is better than any other I know of in a Company with this size of Mkt Cap. Betting the jockey not the horse.

cheers

cheading

[don muang] 05/5/2007 11:58

Not quite talking to yourself .... I'm still reading this. Of course, with hindsight should have sold out at time of listing in Aus being announced. Didn't - so remain a holder as no point selling now. Bought in early on so not holding at a loss. Don't see much further downside so am keeping this for a while yet...

[cheading] 05/5/2007 11:34

Talking to myself here, no change there then. Come back in three years, all will be different.

cheers

cheading

[cheading] 02/5/2007 19:28

Chairman David Dodd, has been there, got several T-shirts. His last Co went from $85 million to $1.4 billion. Back the jockey, not the horse, springs to mind. Tucked well in bottom drawer so I'll not be tempted to bail too soon. Years of growth lie ahead, with enough cash in Bank. Dontcha just love small (for now) Caps.

cheers

cheading

[samuri19] 28/4/2007 10:12

Pradip,

Thanks for your informed view. This seems to be a longer term play.
The sells seem to be being soaked up by buyers...always a good sign.

[pradip44] 27/4/2007 23:36

The steam is running out Stem .. looking at the graph its a classic Ayers rock ... man

[samuri19] 27/4/2007 13:02

Stock seems to be consolidating at these levels. Big sells going through today
but the MM's seem to be soaking it up (some sells being offered premium price).
Maybe we have a buyer in the back-ground.

Company needs to get active and produce a steady stream of news flow. This is a real cutting edge sector to be in, but the company (at the moment) seem unable to transfer that towards the share price.

Any other views would be appreciated (if there is anyone else out there).

[pradip44] 23/4/2007 22:03

is that you .... Mr Valera ?

[parvez] 12/3/2007 14:57

Guys,
I am out as only bidding for 5k and offering 10k - Only Winterfloods on the offer and too risky for me...
Cheers
Parv

[vpatel25] 09/3/2007 17:59

Dave-W, Thanks for your reply

[dave-w] 09/3/2007 13:58

VP, I use Wills and Co in the main for small cap stuff. But I can't say I rave about them. Their recommendations have yet to come good on average for me and, although their buying deals can be attractive, (usually when they've made a packet as principle!) their selling costs are not cheap.

[vpatel25] 08/3/2007 15:38

Dave-W....Which broker do you use? I use TD Waterhouse and was thinking of changing?

[dave-w] 08/3/2007 13:48

mmmm... seems like we're getting noticed at last. But this is quite a rise, I wonder what's driving it? Odd thing is that sells outweigh buys by quite a margin today... yet still we rise?

[don muang] 07/3/2007 17:08

moving up nicely .... pity about the spread though (and the nms)

[bobby.ifa] 21/2/2007 20:50

Thanks dave, bought 4k to-day on spec, would like to top-up when I feel more confident on progress.
Looks under-valued and underlooked.
Bon voyage!

[dave-w] 21/2/2007 19:20

Haven't tracked it down yet but my broker told me today that STEM's house broker issued a healthy buy note following the MERCK announcement(see header). The share price certainly seemed to react accordingly. This looks increasingly encouraging IMHO.
rgds.

[don muang] 01/2/2007 08:06

The Indepndent newspaper had this a few days ago and now the Beeb has picked it up ....

Branson to launch stem-cell bank

[don muang] 25/1/2007 16:43

and just to re-state part of the last part of todays RNS concerning Millepore:
The Company is part of the S&P 500 index and employs approximately 5,800 employees in more than 47 offices worldwide.

[786abdul] 25/1/2007 14:12

Stem Cell Sciences plc
25 January 2007


25 January 2007

Millipore's HEScGRO(TM) Medium Advances Human Embryonic Stem Cell Research

As a direct result of an agreement between Millipore and Stem Cell Sciences,
announced in October 2006, Millipore Corporation have today announced the
availability of HEScGRO animal component-free medium for human embryonic
stem cell research.

HEScGRO medium is the first commercially available animal component-free medium
tested successfully for human embryonic stem cell culture and shown to maintain
hES cells in their undifferentiated state. The agreement between Millipore and
Stem Cell Sciences signed in October 2006 made it possible for Millipore to
manufacture and market SCS' serum-free media with SCS receiving royalties from
all future sales of HEScGRO.

HEScGRO's unique serum-free, ready-to-use and complete formulation offers new
ease and reliability in growing human embryonic stem cells. Media containing
animal-derived components are subject to wide variability and may contain
factors that promote differentiation of hES cells,as well as containing toxic
proteins or immunogens that can adversely affect the cells themselves, HEScGRO
medium is a defined, animal component-free formulation that successfully
addresses these problems and allows scientists to grow human stem cells with
confidence.

Commenting on the availability of HEScGRO, David Dodd, Chairman of Stem Cell
Sciences, said:

'We're very pleased with this agreement with Millipore Corporation and look
forward to the success of this unique new product.'

- Ends-

For further information, please contact:
Stem Cell Sciences plc
David Dodd, Non-Executive Chairman of Stem Cell Sciences
Hugh Ilyine, Vice President and Chief Operating Officer 0131 662 9829

Weber Shandwick Financial
Louise Robson
James White 020 7067 0700

Notes to Editors
Stem Cell Sciences plc (SCS, AIM: STEM) is a global biotechnology company,
established in Melbourne, Australia in 1994, providing products in the
burgeoning stem cell research and drug discovery markets, in addition to the
targeted development of cell-based therapies for neurodegenerative disease and
injury.

The Company has established a leading intellectual property (IP) and technology
portfolio that enables the commercial application of stem cells in drug
discovery, providing the Company with early-stage revenue streams and technology
development for at scale cell production of SCS cell-based therapeutics. SCS
principal focus is in neurological disease. Revenues in the neurotech market,
including pharmaceuticals, devices and diagnostics, grew 10% in 2005 to US$110
billion (Neurotech Insights, Volume 2/3 April 30 2006).

SCS operates as a group of independent operations with laboratories in Scotland,
Japan and Australia, each of which is affiliated with an academic centre of
excellence. These include the Institute of Stem Cell Research (ISCR), Edinburgh,
UK, RIKEN Centre for Development Biology, Kobe, Japan and the Australian Stem
Cell Centre, Melbourne, Australia.

SCS has four business units focused on key sustainable business strategies.

SC Proven(R) provides cell culture media (liquid formulations) and reagents that
enable the growth and differentiation of stem cells. The first commercially
available product, a novel, serum free, stem cell growth medium, has been
exclusively licensed for manufacture and marketing to Chemicon, part of
Millipore Corporation.

SC Licensing licenses SCS proprietary technologies, such as Internal Ribosome
Entry Site (IRES) and Stem Cell Selection, for application in laboratory-based
research and discovery. SCS has licensed technology to major pharmaceutical and
biotechnology companies including Pfizer, Sanofi Aventis, GSK, Deltagen Inc and
Lexicon Genetics Inc.

SC Services provides specialised stem cell production for basic research and
drug discovery, including high-throughput applications.

SC Therapies' goal is to develop safe and effective cell-based therapies for
currently incurable diseases. SCS is conducting preclinical evaluations of its
neural stem cell lines in a number of therapeutic applications. The first
preclinical programme is being undertaken by SCS' Japanese affiliate, which
recently announced the exclusive licensing of human multi-potent adipose-derived
stem (hMADS) cells for therapeutic purposes. SCS KK will conduct preclinical
studies for the treatment of Duchenne Muscular Dystrophy in 2007-8.

For further information on the company please visit:

www.stemcellsciences.com


About Millipore
Millipore is a leading provider of products and services that improve
productivity in laboratory research and bioprocessing manufacturing sites.
Through its broad product portfolio, the Company drives growth through
innovation and delivers higher value-added applications to the marketplace.
Millipore experts have a comprehensive understanding of customers' research,
which results in superior tools, technologies and services. The Company is part
of the S&P 500 index and employs approximately 5,800 employees in more than 47
offices worldwide. For additional information on Millipore Corporation, please
visit
www.millipore.com
.

[don muang] 07/1/2007 11:52

Also looks like the 'Hybrid animal-human embryos face ban' is actually beneficial for STEM. The hydrid proposal was put forward as a way around the present cost / shortage of human eggs.

[786abdul] 07/1/2007 09:05

Biotech shares rise on stem cell bill
BY MATTHEW PERRONE


WASHINGTON

Shares of biotech companies working on stem cell-related therapies surged Thursday as Democrats in Congress prepared to promote once again legislation that would increase government-funded research in this area.

House Democrats are expected to propose a bill on Friday that will expand the types of stem cell research that can be funded by the government. In 2001 President Bush said his administration would only allow funding for research using a limited number of stem cell types, and last summer he vetoed a bill passed by Congress that would have eased those limits. It was the first and only veto of his presidency.

With a new majority in Congress -- and support from many Republicans -- House Democrats have promised to push the legislation through in their first 100 hours in power. A House vote is scheduled for next Thursday.

If Bush rejects the bill again, the 100-member Senate is believed to have enough support to overturn his veto with a two-thirds majority vote, though the 435-member House would have a more difficult time getting the necessary votes.

Even if the current legislation does not get through, stem cell research advocates say lawmakers could get it passed down the road by attaching it to a critical bill that the President would have to sign.

"We're hopeful that the president learned something from election results, but if he didn't and chooses to veto this bill again, that doesn't mean the game is up," said Sean Tipton, President of the Coalition for the Advancement of Medical Research.

Many states already decided not to wait for federal money to fund stem cell research. California's Institute for Regenerative Medicine is expected to deliver $181 million this year to scientists working on stem cell-related cures in that state. New Jersey, Connecticut, and Maryland are among the other states that have designated funding for stem cell researchers.

With the possibility of increased funding on the horizon, traders sent the price of Stemcells Inc. stock up more than 15 percent. Shares rose 48 cents, or 18 percent, to $3.14 in midday trading on the Nasdaq Stock Market.

In November the company helped perform the first ever transplant of cells from an aborted fetus into a living patient as part of an experimental treatment for Batten's disease, a neurological disorder.

Shares of tissue repair developer Aastrom Biosciences rose 18 cents, or 14.52 percent, to $1.42 on the Nasdaq. The Ann Arbor, Mich.-based company is aiming to use stem cells to regrow bone and regenerate tissue.

Shares of Alameda, Calif.-based Advanced Cell Technology also rose more than 14 percent on possibility of federal funding could soon flow to the stem cell therapy innovator.

Shares rose 8 cents, or 14.6 percent, to 63 cents on the over-the-counter market.

Last summer Advanced Cell Technology came to national attention after it revealed a technique to grow stem cells from a single human cell taken from a human embryo. Previous methods for harvesting stem cells require the destruction of human embryos, which many people, including President Bush, see as unethical.

Fellow California biotech company Cord Blood America saw its shares rise two cents, or 30 percent, to 12 cents on the over-the-counter market. The company collects and preserves umbilical cord blood from newborn infants for use in future stem cell treatment. Cord Blood issued a release Thursday stating that blood collected by the company was used for the first time in the treatment of childhood leukemia by doctors at the University of Pennsylvania.